• About Us  > 

ABOUT NOTCH.

Founded in 2018, with sites in Toronto, Vancouver, and Seattle, Notch is working to maximize the benefits and reach of new generations of cellular immunotherapies.

We have developed our UNi-T Cell derived from induced pluripotent stem cells (iPSCs). This means:

  • Our approach is to make T cell therapies more drug-like, with a uniform and consistent off-the-shelf drug product that can be delivered to patients at the time of diagnosis.
  • We are developing persistent and potent cell therapies with patient experience and access in mind.
  • Our iPSC-derived UNi-T Cells demonstrate durable and robust tumor control.
  • Our proprietary, scalable manufacturing approach enables unprecedented cost effectiveness and accessibility for patients.
---
 

VANCOUVER, BRITISH COLUMBIA

  • Corporate Headquarters
  • Systems Biology
 

SEATTLE, WASHINGTON

  • Product Development / Preclinical Sciences
 

TORONTO, ONTARIO

  • Advanced Cell Manufacturing
  • Product Development / Preclinical Sciences

With offices in Vancouver, Seattle, and Toronto, Notch Therapeutics operates on the traditional, ancestral, and unceded territories of the Musqueam, Squamish, and Tsleil-Waututh Nations; the ancestral land of the Duwamish, Suquamish, Stillaguamish, and Muckleshoot people; and the Treaty Lands and Territory of the Mississaugas of the Credit First Nation as well as the traditional territory of the Huron-Wendat and Haudenosaunee peoples. We thank these First Peoples who continue to live on these lands and care for them, and whose relationship to these lands existed long before the founding of Canada or the United States of America.